CO-EXISTENCE OF CYP2C19*1/*2 AND ABCB1C.3435 CT GENOTYPE HAS A POTENTIAL IMPACT ON CLINICAL OUTCOME IN CAD PATIENTS TREATED WITH CLOPIDOGREL
Nestorovska KA, Naumovska Z, Staninova Stojovska M, Sterjev Z, Dimovski A, Suturkova Lj
*Corresponding Author: Aleksandra Kapedanovska Nestorovska, PhD, Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, RN Macedonia, Mother Theresa str 47, 1000 Skopje, R. North Macedonia, Email address: alka@ff.ukim.edu.mk
page: 35
|
|
REFERENCES
1. Harnek J, James S, Lagerqvist B. Coronary Artery
Perforation and Tamponade ― Incidence, Risk Fac-
tors, Predictors and Outcomes From 12 Years’ Data
of the SCAAR Registry ―. Circulation Journal.
2020;84(1):43-53.
2. Beitelshees AL, Voora D, Lewis JP. Personalized anti-
platelet and anticoagulation therapy: applications and
significance of pharmacogenomics. Pharmgenomics
Pers Med. 2015;8:43-61.
3. Siasos G, Oikonomou E, Zaromitidou M, Kioufis S,
Kokkou E, Mourouzis K, et al. Clopidogrel response
variability is associated with endothelial dysfunction
in coronary artery disease patients receiving dual anti-
platelet therapy. Atherosclerosis. 2015;242(1):102-8.
4. Johnston SC, Easton JD, Farrant M, Barsan W, Con-
wit RA, Elm JJ, et al. Clopidogrel and Aspirin in
Acute Ischemic Stroke and High-Risk TIA. New
England Journal of Medicine. 2018;379(3):215-25.
5. Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-
guided antiplatelet therapy: promises and pitfalls.
Pharmacogenomics. 2020;21(12):889-97.
6. Zabalza M, Subirana I, Sala J, Lluis-Ganella C,
Lucas G, Tomás M, et al. Meta-analyses of the as-
sociation between cytochrome CYP2C19 loss- and
gain-of-function polymorphisms and cardiovascular
outcomes in patients with coronary artery disease
treated with clopidogrel. Heart. 2012;98(2):100-8.
7. Zhu WY, Zhao T, Xiong XY, Li J, Wang L, Zhou Y, et
al. Association of CYP2C19 Polymorphisms with the
Clinical Efficacy of Clopidogrel Therapy in Patients
Undergoing Carotid Artery Stenting in Asia. Sci Rep.
2016;6(25478).
8. Amin AM, Sheau Chin L, Azri Mohamed Noor D, Sk
Abdul Kader MA, Kah Hay Y, Ibrahim B. The Per-
sonalization of Clopidogrel Antiplatelet Therapy: The
Role of Integrative Pharmacogenetics and Pharma-
cometabolomics. Cardiology Research and Practice.
2017;2017:8062796.
9. Qian W, Chen L, Zhang L, Gao M, Wang C, Qian X,
et al. Comparison of ticagrelor and clopidogrel in
the treatment of patients with coronary heart disease
carrying CYP2C19 loss of function allele. J Thorac
Dis. 2022;14(7):2591-601.
10. Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sa-
batine MS, Stein CM, et al. Clinical Pharmacoge-
netics Implementation Consortium Guideline for
CYP2C19 Genotype and Clopidogrel Therapy: 2022
Update. Clin Pharmacol Ther. 2022;112(5):959-67.
11. Hodges LM, Markova SM, Chinn LW, Gow JM,
Kroetz DL, Klein TE, et al. Very important pharma-
cogene summary. Pharmacogenetics and Genomics.
2011;21(3):152-61.
12. Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. ABCB1
C3435T polymorphism and response to clopidogrel
treatment in coronary artery disease (CAD) patients:
a meta-analysis. PLoS One. 2012;7(10):9.
13. Stokanovic D, Nikolic VN, Konstantinovic SS,
Zvezdanovic JB, Lilic J, Apostolovic SR, et al. P-Gly-
coprotein Polymorphism C3435T Is Associated with
Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel
Concentration. Pharmacology. 2015;97(3-4):101-6.
14. Wang X-q, Shen C-l, Wang B-n, Huang X-h, Hu
Z-l, Li J. Genetic polymorphisms of CYP2C19*2
and ABCB1 C3435T affect the pharmacokinetic
and pharmacodynamic responses to clopidogrel in
401 patients with acute coronary syndrome. Gene.
2015;558(2):200-7.
15. Hidayat R, Rasyid A, Harris S, Harahap A, Herqu-
tanto, Louisa M, et al. Correlation P2Y12 Genetic
Polymorphism As Risk Factor of Clopidogrel Resist-
ance in Indonesian Stroke Patients. Vasc Health Risk
Manag. 2023;19:53-61.
16. Su J, Yu Q, Zhu H, Li X, Cui H, Du W, et al. The risk
of clopidogrel resistance is associated with ABCB1
polymorphisms but not promoter methylation in a
Chinese Han population. PLoS One. 2017;12(3).
17. Pan Y, Chen W, Wang Y, Li H, Johnston SC, Simon
T, et al. Association Between ABCB1 Polymorphisms
and Outcomes of Clopidogrel Treatment in Patients
With Minor Stroke or Transient Ischemic Attack:
Secondary Analysis of a Randomized Clinical Trial.
JAMA Neurol. 2019;76(5):552-60.
18. Adamiak-Giera U, Czerkawska A, Olędzki S, Kur-
zawski M, Safranow K, Jastrzębska M, et al. Impact
of selected genetic factors on clopidogrel inactive
metabolite level and antiplatelet response in patients
after percutaneous coronary intervention. Pharmaco-
logical Reports. 2021;73(2):583-93.
19. Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, An-
giolillo DJ, Kereiakes DJ, et al. Dosing Clopidogrel
Based on CYP2C19 Genotype and the Effect on Plate-
let Reactivity in Patients With Stable Cardiovascular
Disease. Jama. 2011;306(20):2221-8.
20. Simon T, Verstuyft C, Mary-Krause M, Quteineh L,
Drouet E, Méneveau N, et al. Genetic determinants
of response to clopidogrel and cardiovascular events.
N Engl J Med. 2009;360(4):363-75.
21. Rossini R, Capodanno D, Musumeci G, Lettieri C,
Lortkipanidze N, Romano M, et al. Safety of clopi-
dogrel and proton pump inhibitors in patients under-
going drug-eluting stent implantation. Coron Artery
Dis. 2011;22(3):199-205.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
